Dr. Jeff Geschwind, M.D.
- University of Pennsylvania
- Boston University School of Medicine
- University of California San Francisco
- Johns Hopkins University School of Medicine
- Yale University School of Medicine/Management
- Diplomate of the American Board of Radiology
- The Dr. Gary J. Becker Young Investigator Award, Society of Cardiovascular and Interventional Radiology
- Merit Award, American Society of Clinical Oncology
- Albert Nelson Marquis Lifetime Achievement Award Who’s Who
- Boston University School of Medicine Distinguished Alumnus Award
- Wilhelm Conrad Roentgen Honorary Lecture, European Congress of Radiology
- University of California San Francisco Radiology Alumni Award
About Dr. Jeff Geschwind, M.D.
Jean-Francois (Jeff) H. Geschwind, MD is currently the Director of Oncology at USA Clinics Group and world-renowned for his research and clinical expertise on liver cancer. He is considered a pioneer and founding father of the new field of Interventional Oncology. He also is consultant for Cage Pharma, a company he founded in 2009, which is focused on developing cancer drugs targeting tumor metabolism, specifically glycolysis, and serves as a scientific consultant for Philips Healthcare advising them on all matters related to oncology and image-guided therapy.
At USA Oncology Centers, Dr. Geschwind is responsible for the development of specialized centers dedicated to the care of cancer patients using minimally invasive image-guided procedures, known as interventional oncology treatment. He has devoted the last decade of his career to the development of Interventional Oncology both as a professor at Johns Hopkins University and Yale School of Medicine, during his tenure as Chairman of the Department of Radiology and Biomedical Imaging.
Dr. Geschwind is recognized worldwide as an expert and key opinion leader in liver cancer. He was the lead or co-investigator on more than 50 clinical trials, some care changing, testing innovative treatments for liver cancer patients funded by pharmaceutical companies, foundations, and the National Institute of Health (NIH). He also received multiple patents for research on a new promising drug that targets a specific pathway in cancer cells, which led to the creation of start-up Cage Pharma based on this discovery.
As a clinician, he has concentrated his efforts on innovative treatments for liver cancer. While at Johns Hopkins, he founded the Center of Oncologic Interventions, which utilized revolutionary imaging technology in collaboration with Philips Health Care (partly supported by funding from the NIH) to visualize tumors, target them with exquisite precision and, as a result, treat them more effectively. After receiving an RO1 grant from the NIH in 2005, he also established his research laboratory to focus on cancer therapeutics that specifically block tumor glycolysis in cancer cells. He has received numerous foundation, industry, and federal grants for his research throughout his academic career both at Johns Hopkins and Yale.
Dr. Geschwind has presented keynote addresses and lectures at many prestigious institutions, received numerous awards (American Society of Clinical Oncology, Society of Interventional Radiology and American Roentgen Ray Society among many), and has published nearly 300 manuscripts in leading scientific journals. He was recognized as a Top Doctor by US News and World Report and listed as a top cancer doctor by Castle Connolly.
Making a Difference
We’re here for you
We believe that the patient-doctor relationship is at the core of medicine. We’re here to help you through your cancer journey - emotionally, physically and financially.Schedule Online